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Retroviral Transduction of Human Progenitor Cells: Use of Granulocyte Colony-Stimulating Factor Plus Stem Cell Factor to Mobilize Progenitor Cells In Vivo and Stimulation by Flt3/Flk-2 Ligand In Vitro
By Ngaire J. Elwood, Helen Zogos, Tracy Willson, and C. Glenn Begley
The clinical application of gene transfer is hindered by the availability of the multipotential stem cells and the difficulty in obtaining efficient retroviral transduction. To assess potential means by which gene transfer into human hemopoietic stem cells might be enhanced, the retroviral transduction efficiency of human bone marrow cells (BM) or peripheral blood progenitor cells (PBPC) was compared at multiple time points after in vivo administration of granulocyte colony-stimulating factor (G-CSF). This was further compared with the transduction efficiency of cells mobilized with G-CSF plus stem cell factor (SCF) in a cohort of patients randomized t o receive either one or two growth factors and with normal B M function. Using the LNL6 retrovirus, retroviral transduction efficiencies of up t o 19% were observed for both PBPC and BM (n = 26 patients). There was at least a 100-fold increase in PBPC with G-CSF alone and a further R ETROVIRAL VECTOR-mediated gene transfer into human hematopoietic cells is currently under investigation in a number of clinical studies. However, obstacles to the more widespread clinical application of gene transfer into hematopoietic cells include the scarcity of the available target cells and the relative inefficiency of retroviral transduction. Studies in recent years have shown that administration of granulocyte colony-stimulating factor (G-CSF) causes up to 100-fold increase in peripheral blood progenitorlstem cells (PBPC),' including more primitive cells,' and that these can be harvested for clinical benefit. ' Stem cell factor (SCF; also known as KL or SLF) is the ligand for the tyrosine kinase receptor, c-kit. This molecule stimulates the proliferation of both myeloid and lymphoid cells and, in combination with other cytokines, displays potent synergistic actions.'.' When administered to mice' or baboon^,^ an increase in PBPC is observed and these cells are capable of long-term repopulation in lethally irradiated recipients. A further increase in both short-term and longterm repopulating cells in mice was observed using a combination of SCF plus G-CSF compared with G-CSF alone."'"
In addition, in vivo administration of SCF plus G-CSF to baboons has been shown to stimulate a greater than 10-fold increase in PBPC compared with G-CSF alone." Preliminary results of phase I/II clinical studies with SCF plus G-CSF to mobilize PBPC indicate that dose-related increases occur in granulocyte-macrophage colony-forming cells (GM-CFC), burst-forming units-erythroid (BFU-E), and CD34' cells in patients receiving a combination of SCF plus G-CSF compared with that of G-CSF alone.'2." Thus, growth factormobilized PBPC potentially offer a population of early hematopoietic cells that may be amenable to retroviral infection. Although there have been several reports indicating that mobilization of PBPC with a combination of chemotherapy and cytokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], G-CSF, and interleukin-3 [IL-3]) allows efficient retroviral transdu~tion,""~ it is difficult to assess the relative contribution of growth factors in these studies. This study was therefore performed to document the efficiency of retroviral gene transfer into cells from patients, at multiple time points, randomized to receive either G-CSF alone or SCF plus G-CSF to mobilize PBPC.
In an attempt to improve the infection efficiency of hematopoietic cells, the combination of cytokines present during the retroviral transduction period was examined. The Flt3/ Flk-2 tyrosine kinase receptor is closely related to the receptor for SCF (c-kit) and, like SCF, the Flt3/Flk-2 ligand (FL) has been shown to synergize with a number of cytokines in the human"-2" and murine system.lx.2'-24 Receptors for FL are selectively expressed by enriched progenitor/stem cell populations and FL stimulates the proliferation of these ~e l l s .~'~~~ We therefore examined whether addition of FL during the transduction period was able to improve infection efficiency of human hematopoietic cells. 5, 8 , and 12 after commencement of treatment with growth factor(s); on day 1, the blood was collected before the administration of growth factor. Subsequently, patients received high-dose chemotherapy, and the PBPC collected during the period of growth factor administration were reinfused. This phase of the clinical study was not included in the analysis presented here. All aspects of this study were approved and monitored by the Institutional Ethics Committee.
MATERIALS AND METHODS

Cells
Retroviral vector. The LNL6 retrovirus was produced using the PA3 17 amphotropic retrovirus packaging cells containing the LNL6 ~e c t o r~~. ' " which carries the neomycin phosphotransferase gene and confers resistance to (3418. The retroviral titer of this packaging cell line was consistently between 5 X IO6 and 1 X 10' infectious units (IU)/mL as assessed using an NIH3T3 assay." To ensure a comparable titer over the time of these studies, stocks from a single hightiter clone were thawed every 2 months and viral titer confirmed by NIH3T3 assay at approximately 1 X IO' IU/mL. The producer cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) high glucose (0.45% glucose) supplemented with 10% bovine calf serum (BCS) and, where required, vector-containing supernatants were collected from confluent cells, filtered, and frozen at -70°C. Titer of viral supernatants was repeatedly confirmed.
CD34' cell selecfion. CD34' cells were selected using the Miltenyi MiniMacs Immunomagnetic Separation system and the CD34' progenitor cell isolation kit (Becton Dickinson, Knoxfield, Victoria, Australia) with slight modification of the manufacturer's instructions. Briefly, mononuclear cells (MNC) from BM samples or PBPC were isolated by centrifugation on Ficoll density gradient and suspended in Iscove's modified Dulbecco's medium (IMDM) and 20% fetal calf serum (FCS). A total of IO' to 3 X IO' MNC were incubated with 150 pL of degased buffer/lO' cells (phosphate-buffered saline supplemented with 0.5% bovine serum albumin and 5 mmoVL EDTA, pH 7.2). Fifty microliters of reagent A1 (human IgG) was mixed with 50 pL of reagent A2 (modified CD34 antibody, QBENDl 10, mouse IgGl) per 10' cells and incubated for 15 minutes at 4°C. Cells were washed once in 5 mL buffer/lOs cells and then resuspended in 200 pL/108 cells. Reagent B (50 pWl0' cells; colloidal superparamagnetic MACS microbeads recognizing reagent A2) was added and incubated for 15 minutes at 6°C. Cells were washed once and resuspended in 400 pL buffer/lO' cells. Cells were then applied to the MiniMacs magnetic column (type MS, without flow resistor), allowed to pass through the column, and washed with 4 x 500 pL buffer. The column was removed from the magnet, 1 mL of buffer was added to the column, and the cells were eluted. The purity of the isolated cells was assessed by staining cells with the CD34 antibody (HPCA-2; Becton Dickinson) before analysis with a fluorescence activated cell analyzer (Coulter Electronics Profile 11, Hialeah, FL). The purity of the CD34+ fraction was consistently between 90% and 96%.
Retrovirat transduction. MNCs from BM or blood (2.5 X lo6 cells) or CD34'-purified cells (2.5 X lo5 cells) were cocultivated for 3 days (37°C 5% CO,) in 60-mm dishes (Falcon; Becton Dickinson, Lincoln Park, NJ) with lo6 irradiated (3,000 rad) PA317LNL6 retrovirus producer cells. For all experiments, control or mock-cocultivations were performed, using the packaging cell line PA317. For retroviral transductions performed using viral supernatant (titer at approximately lo7 IU/mL), supernatant was added at a final dilution of 1:lO and supplemented daily. Control transductions were performed using media in place of supernatant-containing virus. All retroviral transductions were performed in 5 mL IMDM/10% FCS in the presence of the following concentrations of IL-3 (100 ng/mL), L-6 (100 ng/mL), GM-CSF (100 ng/mL), SCF (100 ng/mL), G-CSF (500 U/mL), and 4 pg/mL polybrene (Sigma, New South Wales, Australia). These cytokines were recombinant human proteins provided by AMGEN (Thousand Oaks, CA). In an attempt to improve retroviral transduction efficiency, the cytokines listed above were added in various combinations with or without a supermaximal concentration of purified recombinant murine FL (FL; 100 ng/mL'*) during the cocultivation period. Recombinant FL was produced as previously described?','* Both BM and PBPC from all of the abovementioned mobilization regimens were used as the source of cells for the FL experiments. After retroviral transduction, nonadherent cells were collected and the efficiency of infection was determined by progenitor cell assay in the presence of G418.
Progenitor cell assay. Progenitor cells were grown in agar culture prepared by adding l v01 of double-strength asparagine IMDM (AIMDM) and 1 v01 of FCS to 2 v01 of 0.6% agar (Difco Laboratories, Detroit, MI) in a final volume of 1 mL." Cultures were stimulated by purified, recombinant human GM-CSF (100 ng/mL), G-CSF (500 U/mL), and SCF (100 ng/mL) for granulocyte-macrophage progenitor cells (GM-CFC) and GM-CSF ( I 00 ng/mL), IL-3 (100 ng/mL), IL-6 (100 ng/mL), SCF (100 ng/mL), and erythropoietin (EPO; 2 U/mL) for erythroid progenitors (BFU-E). Cells from BM were cultured at concentrations of both lo4 and IO5 and peripheral blood (PB) at both 2 X IO4 and 1 X lo5 cells/dish. CD34' cells were cultured at both 1 X lo3 and 3 X IO3 cellddish. To determine the efficiency of retroviral infection, cultures were grown in the presence or absence of G418 (active concentration, 2 mg/mL; Life Technologies, Melbourne, Australia). To accurately quantitate progenitor cells, multiple replicate cultures were examined; results shown for colonies grown in G418 are the mean of 9-replicate cultures. All other results are the mean of triplicate cultures. The percentage of infection efficiency was defined as the number of (3418-resistant (G418R) CFC as a function of the total number of CFC, multiplied by 100. The retroviral infection efficiencies reported throughout this study were assessed by ability to confer resistance to G418 and, as discussed below, probably underestimated the true retroviral transduction efficiency.
Cultures were incubated in a fully humidified atmosphere of 5% CO2 in air at 37°C for 14 days. Replicate cultures were scored for colonies (>40 cells) after 14 days using a dissection microscope at 35 X magnification.
Polymerase chain reaction (PCR). In 3 experiments, PCR to detect the NeoR gene was performed on DNA extracted from 90 individual CFC colonies. Individual colonies were plucked from agar culture into 50 pL water. Samples were heated to 99°C for 10 minutes, digested with proteinase K (0.4 mg/mL; Worthington Biochemical Corp, Freehold, NJ) at 55°C for 60 minutes, heated again to 99°C for IO minutes, and then kept on ice. DNA (6 pL) was amplified in a 50 pL reaction containing 200 pmoVL dNTPs, 1 p m o K oligonucleotide primers, 1.25 U Tay polymerase (Boehringer Mannheim, Germany), and the supplied reaction buffer. PCR was performed using a Hybaid Omnigene Thermal Cycler (Hybaid, Teddington, UK). Cycle conditions were 94°C for 2 minutes, 55°C for 2 minutes, and 72°C for 3 minutes, with 7 minutes of extension time for the last cycle. Reactions were performed for 35 cycles. The sequence of PCR primers to detect the NeoR gene (353-bp fragment) was sense GAATGAACTGCAGGACGAGG and antisense TI'G-AGCCTGGCGAACAGTI'C. PCR products were anlayzed by electrophoresis through 1.2% agarose gels ( 
G-CSF + SCF
Abbreviation: NT, sample not tested. ATCATGGCTGATGC) internal to the primers used for PCR. Oligonucleotides were labeled by addition of a radioactive 5' y phosphate using polynucleotide kinase. After overnight hybridization, filters were washed to a final stringency of 6X SSC at 55°C and then autoradiographed. In all experiments, NeoR DNA was not detected in the samples used as negative controls (viz water alone, K562 DNA, and DNA from colonies after mock-cocultivation using PA3 17).
Statistical analyses. Statistical analyses of the SCF/G-CSF patient data were performed using either an unpaired Student's t-test or the Mann-Whitney test, as indicated within the text. Statistical analysis of the FL data was performed using a paired Student's ttest.
RESULTS
Growth factor-mobilized cells are not more eficiently transduced by retrovirus. Initial experiments examined the retroviral transduction efficiency for normal BM-derived GM-CFC and BFU-E. Transduction efficiency was determined using colony growth in cultures containing 2 mg/mL G418. This concentration of G418 was higher than that usually used by others (usually 0.8 to 1.2 This concentration was selected based on titrations of G418; occasionally, spontaneously G418R CFCs were observed at concentrations up to 1.6 mg/mL (data not shown). An active concentration of 2 mg/mL was therefore deliberately used throughout these studies as a stringent selection for transduced cells expressing high levels of neomycin phosphotransferase. PCR was performed on DNA extracted from individual GM-CFC and BFU-E colonies. This was performed as an independent indicator of transduction efficiency. In three experiments, the NeoR gene was detected by PCR in 39%. 68%, and 79% of colonies that were grown in cultures without G418 (total of 90 colonies examined). The extent of gene transfer in the same three experiments, as assessed by colony formation in the presence of G418, was much lower (ie, 0.1%, 7%, and 3%, respectively). These findings are consistent with results of similar and may reflect the loss of neomycin phosphotransferase expression as cells in the hematopoietic colonies differentiate.17
As expected from earlier ~tudies,~' there was a broad interindividual variation in number of GM-CFC (from 1.6% to 17.5% BM GM-CFC transduced). A similar variation was seen with BM-derived BFU-E, ranging from 50.1% to 6.5% (n = 17 examined, representative examples shown in Table  1 ). Retroviral transduction efficiency was similar for resting blood samples (day 1) when compared with bone marrow samples from that individual. For all cell samples, gene transfer into BFU-E was consistently less than observed with Treatment of patients with G-CSF alone did increase the number of retrovirally infected PBPC (GM-CFC and BFU-E)/105 MNCs compared with baseline blood samples (day 1). The median number of G418R GM-CFC/105 cells at days 1, 5 , and 8 was 1, 13, and 18, respectively, for patients receiving G-CSF alone (Fig IA) . By day 12, the total number of retrovirally infected cells returned to near-baseline levels GM-CFC ( P < (median, 4 G418R GM-CFC/105 cells). A similar pattern was observed for G418R BFU-E/lO' cells, although the median values for BFU-E were usually at least twofold lower than for GM-CFC (Fig 1B) . This increase in gene transfer paralleled the overall increase in progenitor cells observed in this study and previously noted with G-CSF' and thus reflected an increase in the total number of PBPC/105 MNCs in the blood. However, despite the increase in the total number of transduced cells, there was no consistent change in efficiency of gene transfer after in vivo administration of G-CSF (Table  1) . For example, at the peak level of PBPC after 5 days of treatment with G-CSF, the infection efficiency of GM-CFC was 0.7% to 18.6% (n = lo), compared with 50.1% to 12.4% (n = 17) for baseline PB ( P = .20).
Retroviral transduction efficiency of PBPC mobilized with the combination of SCF plus G-CSF was therefore compared with transduction of G-CSF-mobilized PBPC. As noted above, there was a wide variation between individuals in the number of cells transduced. However, the baseline values were comparable between the two groups: equally low levels of blood GM-CFC and BFU-E were retrovirally marked at this time (median of < M O 5 progenitor cells and a median of 36 BM GM-CFC per lo5 cells were G418R). This finding suggested that the two patient groups were similarly matched (Fig 1A) .
Treatment of patients with SCF plus G-CSF did not alter the proportion of retrovirally infected progenitor cells when compared with G-CSF alone. After treatment with SCF plus G-CSF, the median number of G418R GM-CFC at days 1, 5, and 8 was 0.6, 13, and 14, respectively. This was similar to that observed for G-CSF alone (Fig IA) . At day 12, there was the suggestion of a difference between the two cohorts (median, 7; range, 2 to 93 G418R GM-CFC/105 cells for SCF plus G-CSF; v median, 4; range, 0.3 to 8 G418R GM-CFC/lOS cells for the G-CSF group; P = .l). A similar pattern was observed for G418R BFU-E/105 cells (Fig 1B) . The difference at day 12 between the two groups reflected a difference in the total number of GM-CFC/105 cells (median, 287; range, 130 to 750 GM-CFC/105 cells for SCF plus G-CSF compared with median, 81; range, 33 to 232 GM-CFC/ 10' cells for G-CSF alone; P < .01).
Thus, somewhat surprisingly, there was no consistent change in retroviral transduction efficiency of PBPC after treatment with G-CSF alone. Similarly, there was no increase in transduction efficiency after SCF plus G-CSF. However, in some individuals (eg, patient no. 8 in Table l ), this may have occurred. The variability between individuals in terms of percentage of cells retrovirally transduced was also unaltered by the administration of growth factor. Therefore, the administration of G-CSF or a stem cell-active molecule, SCF, did not enhance the ability to retrovirally infect PBPC populations.
Treatment of patients with SCF plus G-CSF increased the number of retrovirally transduced cells compared with G-CSF treatment alone. Treatment of patients with SCF plus G-CSF increased the absolute number of retrovirally transduced GM-CFC and BFU-E per milliliter of blood by up to 30-fold when compared with G-CSF alone. Baseline values (both G418R BM cells and day 1 G418R PBPC) were the same for the two groups (Fig 1) . The difference between the SCF plus G-CSF cohort versus G-CSF alone cohort was most evident at day 12 (median, 230 G418R GM-CFC/mL v 19 G418R GM-CFC/mL, respectively; P < .05, Mann Whitney test). SCF plus G-CSF was also significantly superior at day 8 (1,048 G418R GM-CFC/mL v 533 G418R GMuse only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From CFClmL; P < .05, unpaired t-test). This difference was also evident, although not statistically significant at day 5 (median, 1,451 G418R GM-CFC/mL v 559 G418R GM-CFC/ mL; Fig 2A) . Thus, despite the wide patient to patient variation, this represented an overall increase in the number of retrovirally marked GM-CFC of about twofold at days 5 and 8 and about 12-fold at day 12. Similar results were observed for the number of G418R BFU-E per milliliter (Fig 2B) , with a twofold increase in BFU-E at day 5 and 8 ( P < .05, unpaired t-test) and a 30-fold increase in favor of SCF plus G-CSF at day 12 (P < .01, Mann-Whitney test).
As with the increase in absolute numbers of retrovirally transduced progenitor cells noted with G-CSF above, the increase in absolute numbers of retrovirally transduced GM-CFC and BFU-E was a consequence of the increase in the total number of progenitor cells observed in patients treated with the growth factor combination. The total number of GM-CFC recovered after the 3-day coculture period was a median of 48,315 (day 5), 39,054 (day 8), and 3,936 per milliliter of blood (day 12) with SCF plus G-CSF. In contrast, the median number of GM-CFC recovered per milliliter of blood for patients treated with G-CSF alone was 30,989 (day 5), 1 1,231 (day 8; P < .01, unpaired t-test), and 370 per milliliter of blood (day 12; P < .05, unpaired t-test).
Similar differences were also observed in the total number of BFU-E recovered (data not shown). Together, these resuits indicated that treatment of patients with SCF plus G-CSF did not alter the retroviral infectability of progenitor cells but rather increased the absolute number of progenitor cells available for retroviral marking when compared with mobilization of PBPC using G-CSF alone.
FL in vitro increased retroviral transduction of primary hematopoietic cells. Given that FL supports proliferation of hematopoietic progenitor cells and the requirement of cell cycling for retroviral integration, we examined whether addition of FL during the cocultivation period enhanced retroviral transduction efficiency. Nine different cytokine combinations were examined during the cocultivation period in an attempt to optimize retroviral transduction. The combination of FL plus IL-3 was always superior and consistently produced a twofold to eightfold increase in transduction efficiency above our standard five-factor combination used (n = 28, P < .001). A typical experiment is shown in Fig 3, in which the cocultivation was performed in the presence of the usual combination of five cytokines (IL-3, IL-6, GM-CSF, SCF, and G-CSF), IL-3 alone, FL alone, or FL plus IL-3. The absolute number of GM-CFC or BFU-E detected in the culture system was similar regardless of the cytokine combination. However, FL plus IL-3 produced about a sevenfold increase in the number of G418R GM-CFC compared with the five-factor combination or FL alone. A significant increase in retrovirally transduced BFU-E was also observed with FL plus IL-3. In the experiment shown in Fig 3, this was about twofold greater than the five-factor combination and was always slightly more than the effects seen with IL-3 alone. Although subtle, this erythroid effect was a consistent finding with all patient samples. To exclude the possibility that the effect of FL plus IL-3 was due to an interaction with the fibroblast packaging cell line. we performed four experiments in which retroviral transductions were undertaken using viral supernatant alone. Two examples are represented by patients no. 9 and IO in patient samples transduced in the presence of the usual fivefactor combination or FL plus IL-3 is shown in Fig 4. The presence of FL plus IL-3 gave on average a twofold to eightfold increase in infection efficiency of GM-CFC above that observed using the standard five-factor combination ( P < .OOl). Similarly, an increase in transduction efficiency of BFU-E was also consistently observed (twofold to fivefold: P < .OO1). The effects of FL occurred for both BM and PBPC. There were no apparent differences in the degree of FL effect for the different sample sources. formed by cocultivation. Again, the increase was observed for both GM-CFC and BFU-E. Thus, it appeared that FL plus IL-3 appeared to exert a direct action on CD34' cells in improving retroviral transduction.
Given that FL shares a number of overlapping properties with SCF, it was interesting to note that the combination of SCF plus IL-3 did not have the same effect in enhancing retroviral transduction efficiency as did R. plus IL-3 (Fig S) . In fact, the addition of SCF to the FL plus IL-3 combination appeared to abrogate this effect; representative examples are shown in Fig S. For each patient sample, the absolute number of GM-CFC was similar regardless of the cytokines present during the cocultivation. The combination of FL plus IL-3 during the transduction enhanced the number of retrovirally marked progenitor cells for the 4 patients approximately fivefold. In contrast, the combination of IL-3 plus SCF produced a similar result to the five-factor combination of cytokines. Moreover, the addition of SCF to the FL plus IL-3 combination showed no enhancement of the retroviral transduction efficiency.
DISCUSSION
The data presented in this study have shown two potential means by which gene transfer into human hematopoietic cells may be improved. Firstly, in vivo administration of SCF plus G-CSF mediated an increase in the number of progenitor cells in the blood available for gene transfer. These cells could be retrovirally transduced as efficiently as Retroviral transduction of mobilized PBPC. Retroviral transduction of mobilized human PBPC has been previously examined by other^.'^"^.^^ However, this is the first comprehensive analysis of gene transfer into human progenitor cells mobilized by cytokines alone and from individuals with no abnormality of bone marrow function. Retroviral transduction of PBPC mobilized by G-CSF alone has been reported to be more efficient than infection of cells mobilized by highdose chemotherapy plus G-CSF.16 However, only 6 patient samples were examined in this study and retroviral transduction efficiency was assessed by specific glucocerebrosidase enzyme activity in transduced PB cells. The infection efficiencies we obtained for PBPC mobilized by either G-CSF alone or SCF plus G-CSF were comparable to those reported by groups for whom cells were mobilized with high-dose chemotherapy plus ~ytokines'','~,~~ but lower than that reported by othersI4; however, the active concentrations of G418 used make it difficult to compare results. In this study, a concentration of 2 mg/mL G418 was used to provide a stringent selection for transduced cells.
Mobilization of PBPC with G-CSF alone increased the number of retrovirally transduced progenitor cells compared with baseline blood samples. The number of genetically marked PBPC at days 5 and 8 was comparable to that observed in normal BM. After withdrawal of G-CSF in vivo, the proportion of retrovirally transduced PBPC had returned towards baseline levels by day 12. These changes observed were not due to increases in the transduction efficiency of the cells per se but probably reflected the increase in total PBPC observed after G-CSF alone.
Mobilization of PBPC with SCF plus G-CSF did not further enhance the proportion of retrovirally marked cells above that observed for G-CSF alone but did increase the total number of PBPC per milliliter of blood available for gene transfer. The difference in the number of G41 8R PBPC per milliliter of blood at day 5 after G-CSF alone or SCF plus G-CSF was not statistically different, although a trend in favor of the Combination was apparent. At days 8 and 12, a statistically significant difference was evident. This was shown by using an unpaired t-test (day 8) and Mann-Whitney test (day 12). The requirement for the Mann-Whitney test reflects the wide interpatient variation and the fewer number of samples analyzed from patients receiving G-CSF alone. However, support is given to the validity of these findings because we conclude that the increase in G418R PBPC per milliliter of blood after SCF plus G-CSF was a reflection of an increase in the total number of PBPC per milliliter of blood (which was also significantly different at day 8 and 12). Furthermore, the patient samples presented here are a subset of the patient samples analyzed for progenitor cell mobilization in a more extensive study in which the differences between SCF plus G-CSF and G-CSF alone have been further validated (Begley et al, manuscript in preparation) .
The effect of SCF plus G-CSF to increase the number of target cells for gene transfer is consistent with animal data.
In mice, it has been shown that SCF plus G-CSF mobilized at least twofold more long-term repopulating cells and shortterm repopulating cells than did G-CSF alone',' and subsequently led to more sustained engraftment." However, it was surprising that administration of SCF in vivo did not enhance retroviral transduction efficiency. This was particularly so given that SCF enhances the in vitro proliferation of progenitor cells from primate marrow in response to various hematopoietic growth and may play a role in the maintenance of cell cycle:' In addition, SCF in combination with IL-3 and IL-6 has been shown to increase expression of the amphotropic receptor.43 Furthermore, Bodine et ala showed that treatment of splenectomized mice treated with SCF plus G-CSF mobilized large numbers of stem cells into the PB that were more efficiently marked by retroviruses than equivalent cells from the BM of 5-fluorouracil-treated mice. Although there was no control group that received G-CSF alone, a role for SCF in enhanced gene transfer in human gene studies was predicted. Our data suggest that the combination of SCF plus G-CSF in vivo is not superior to G-CSF alone in terms of enhancing efficiency of retroviral transduction of human progenitor cells. For any hematopoietic gene therapy approach it is desirable to show that retrovirally transduced cells are able to provide long-term reconstitution of the patients' hematopoietic system. Although a number of assays have been proposed as alternatives to GM-CFC assays, in the context of gene marking, they are all surrogate assays for cells that provide long-term hematopoietic reconstitution. Moreover, the time-consuming and cumbersome nature of these assays substantially limits their application to clinical studies. For these reasons, we examined gene transfer into progenitor cells. Based on these results, we concluded that in vivo administration of SCF plus G-CSF did not offer any further advantages over G-CSF alone in terms of retroviral infectability of progenitor cells, although it did provide an increase in the number of progenitor cells available for gene marking.
Enhanced retroviral transduction by FLplus IL-3 in vitro. Examination of the number of retrovirally transduced progenitor cells showed that the most efficacious combination of cytokines during retroviral infection was FL plus IL-3. It was of interest that addition of SCF to this combination appeared to abrogate this effect. The combination of IL-3, IL-6, and SCF has been documented as the optimum combination to achieve retroviral transduction of human CD34+ PB" and CD34+ BM'4 cells and has recently been used in a clinical study.'6 The addition of IL-la may also be of benefit.34 In these reported studies, transduction efficiencies ranging from 2% to 50% G418R CFCs were recorded with wide variability in infectivity of patient samples. The infection efficiencies obtained in the current study were comparable with those observed by others and also with wide variation between individuals.
FL plus IL-3 appeared to exert a direct action on CD34' cells in improving retroviral transduction. This effect was seen both in coculture experiments using the packaging cell line and in experiments using the viral supernatant. The presence of FL plus IL-3 during transduction with retroviral use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From supernatant remained up to 10-fold better than the usual combination. In all experiments (n = 28), FL plus IL-3 also enhanced the transduction efficiency of BFU-E above the usual combination. This is not surprising given that CD34+ cells express receptors for FL and display erythroid potentiaL4' Furthermore, antisense studies directed against the FL receptor inhibited BFU-E formation by CD34+ human BM cells." However, FL does not appear to have a direct proliferative effect on committed erythroid
The mechanism by which FL plus IL-3 enhanced retroviral transduction is unknown. It did not appear to be associated with enhanced clonogenicity. There was no consistent difference between the cytokine combinations in terms of the total number of progenitor cells after the transduction period (data not shown). However, enhanced clonogenicity has been shown with murine Lin Sca-l' BM cells" and Thy'" S a l + cells2' stimulated with FL plus IL-3. FL has been shown to increase the clonogenicity of l i n~ kit.' Sca-1. progenitor cells, although leaving the high generative capacity of the more primitive lin-kit+ Sca-1 + cells unaltered." Furthermore, FL plus IL-3 stimulated greater clonogenicity of these cells than FL plus SCF. Thus, it is possible that, rather than enhancing self-generation of the most primitive stem cells, FL may act to generate more mature multipotential cells. However, an action of FL to stimulate selfgeneration has been shown using the MI leukemic cell line." Perhaps with a more highly purified population of CD34' cells, a difference in clonogenic potential may have been observed. Based on the above literature with highly purified murine cells, FL may act to maintain clonogenic potential and possibly facilitate self-renewal, thereby explaining the enhanced retroviral integration that we observed. It is also possible that the combination of FL plus IL-3 altered the cycling status of the progenitor cells, thus allowing more efficient retroviral integration. The FL receptor-positive fraction of primitive cells contains almost 10-fold more cycling cells than the FL receptor-negative subpopulation.47~4x Equally, the combination of FL plus IL-3 may increase amphotropic receptor binding to human stem cells to allow improved retroviral transduction efficiency.
This has been observed after prestimulation of CD34' cells in IL-3, IL-6, and SCF.4' FL plus IL-3 appeared to favor predominantly macrophage and some granulocyte differentiation in liquid culture.'* This preference of FL to generate cells of the myeloid lineage was also observed in morphologic analysis in the current study after the 3-day transduction period (data not shown). However, from both the colony morphology and cell morphology analysis, there was no suggestion that FL plus IL-3 was promoting differentiation beyond that observed using the other cytokine combinations, although the generation of dendritic cells has been noted in similar culture conditions.4y
Whatever the mechanism for the enhanced retroviral transduction efficiency in the presence of FL plus IL-3, this is the first time such a function for FL has been described. It is now of interest to examine whether the long-term repopulating ability of such transduced cells is maintained. Furthermore, the combination of FL plus IL-3 may prove useful for retroviral supernatant infection of mobilized cells for clinical protocols. It may also be useful to include FL in systems involving allogeneic stromal cultures5" or BM extracellular matrix molecules." It would also be of interest to examine the action of FL in clinical PBPC mobilization strategies as an approach to obtaining cells potentially susceptible to enhanced retroviral gene transfer.
nant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. 
